Damora Therapeutics, Inc. Ordinary Shares (DMRA)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 7
- Market Cap
- $1.8B
About Damora Therapeutics, Inc. Ordinary Shares
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
SentiSense also tracks daily options readings for Damora Therapeutics, Inc. Ordinary Shares: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Damora Therapeutics, Inc. Ordinary Shares stock analysis, sentiment tracking, and market intelligence on SentiSense.